ArticleNature reviews. Clinical oncology2020
Frontline immunotherapy for NSCLC - the tale of the tail.
Article in Nature reviews. Clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Immune Checkpoint Inhibitors +/- Chemotherapy for Patients With NSCLC and Brain Metastases: A Systematic Review and Network Meta-Analysis.Thoracic cancer · 2025Pooled it
- Toxicity Profile of Combining PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy in Non-Small Cell Lung Cancer: A Systematic Review.Frontiers in immunology · 2021Pooled it
- Single-cell N4-acetylcytidine regulatory landscape identifies ARIH1 as a ferroptosis-suppressive oncogenic driver in lung adenocarcinoma.Respiratory research · 2026Article
- [Immune checkpoint inhibitor-related pneumonitis : Differential diagnosis strategies].Radiologie (Heidelberg, Germany) · 2026Review
- Second line advanced or metastatic non-small cell lung cancer treatment after chemo-immunotherapy: a retrospective study.Future oncology (London, England) · 2025Article
- Clinical management of checkpoint inhibitor pneumonitis: Focus, challenges, and future directions.Chinese medical journal pulmonary and critical care medicine · 2025Review
- Nonsmall-cell lung cancer treatment: current status of drug repurposing and nanoparticle-based drug delivery systems.Turkish journal of biology = Turk biyoloji dergisi · 2024Article
- CD28/PD1 co-expression: dual impact on CD8Journal of experimental & clinical cancer research : CR · 2023Article
- Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients.Journal of cancer research and clinical oncology · 2023Article
- Article
- Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit.JCO precision oncology · 2022Article
- Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer.Cold Spring Harbor perspectives in medicine · 2022Review
- Immuno-Imaging (PET/SPECT)-Quo Vadis?Molecules (Basel, Switzerland) · 2022Review
- Evaluation of Epidermal Growth Factor Receptor Gene Mutations in an Iranian Population with Non-Small Cell Lung Carcinoma.Iranian journal of public health · 2022Article
- Modulation of chemoimmunotherapy efficacy in non-small cell lung cancer by sex and histology: a real-world, patient-level analysis.BMC cancer · 2022Article
- Case Report: A Programmed Cell Death-1 Inhibitor-Related Abdominal Fibroinflammatory Reaction Affecting Multiple Organs in A Non-Small-Cell Lung Cancer Patient.Frontiers in immunology · 2022Article
- A Joint Model Considering Measurement Errors for Optimally Identifying Tumor Mutation Burden Threshold.Frontiers in genetics · 2022Article
- Validation of Patras Immunotherapy Score model for prediction and prognosis of patients with advanced NSCLC treated with nivolumab or pembrolizumab: results from a European multicentre study.Therapeutic advances in medical oncology · 2022Article
- TMBcat: A multi-endpointFrontiers in immunology · 2022Article
- Therapeutic cancer vaccines revamping: technology advancements and pitfalls.Annals of oncology : official journal of the European Society for Medical Oncology · 2021Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
31907372What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.